Mannkind, Biotech mit Sitz in Kalifornien, hat angekündigt , dass David Kendall seinem Team als Chief Medical Officer beitreten und würde ...
MannKind Corp. buy melinda
Start price
09.03.18
/
50%
€2.46
Target price
10.09.18
€2.93
Performance (%)
-34.68%
End price
10.09.18
€1.61
Summary
This prediction ended on 10.09.18 with a price of €1.61. The BUY prediction by melinda for MannKind Corp. performed very badly with a performance of -34.68%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MannKind Corp. | 5.184% | 5.184% | -15.797% | 13.564% |
| iShares Core DAX® | 3.002% | 4.755% | 23.700% | 68.627% |
| iShares Nasdaq 100 | 2.966% | 0.363% | 8.027% | 116.238% |
| iShares Nikkei 225® | 5.606% | 4.528% | 20.313% | 56.217% |
| iShares S&P 500 | 2.312% | 1.811% | 5.451% | 70.924% |
Comments by melinda for this prediction
In the thread MannKind Corp. diskutieren
Biotechnologie und medizinische SecteurRecherche
Termin
(Laufzeit überschritten)